Pictet Asset Management
RARE icon

Pictet Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Pictet Asset Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.2M Buy
753,695
+150,124
+25% +$3.73M 0.02% 504
2026
Q1 		$11.7M Sell
603,571
-627,760
-51% -$14.1M 0.01% 617
2025
Q4 		$26.6M Sell
1,231,331
-226,856
-16% -$7.46M 0.03% 457
2025
Q3 		$44M Sell
1,458,187
-241,757
-14% -$7.25M 0.04% 347
2025
Q2 		$61.9M Buy
1,699,944
+290,745
+21% +$10.5M 0.06% 284
2025
Q1 		$52M Buy
1,409,199
+235,561
+20% +$9.8M 0.06% 298
2024
Q4 		$49.4M Buy
1,173,638
+653,088
+125% +$32.4M 0.05% 301
2024
Q3 		$28.3M Sell
520,550
-36,268
-7% -$1.85M 0.03% 403
2024
Q2 		$22.9M Sell
556,818
-479,556
-46% -$20.5M 0.03% 436
2024
Q1 		$48.5M Buy
1,036,374
+13,238
+1% +$624K 0.05% 313
2023
Q4 		$48.9M Buy
1,023,136
+153,748
+18% +$5.96M 0.05% 316
2023
Q3 		$31M Buy
+869,388
New +$34.4M 0.04% 362

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Pictet Asset Management's RARE Position: Q2 2026 in Review

Pictet Asset Management increased its Ultragenyx Pharmaceutical (RARE) stake by 25% in Q2 2026, buying an estimated $3.73M and bringing the position to 753,695 shares worth $23.2M. The position accounts for 0.02% of the portfolio, ranked #504.

Pictet Asset Management first reported a position in RARE in Q3 2023 and has held it in 12 quarters since. The position peaked at $61.9M in Q2 2025. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Pictet Asset Management held 753,695 shares of Ultragenyx Pharmaceutical worth $23.2M as of Q2 2026.
  • Pictet Asset Management bought 150,124 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $3.73M.
  • Ultragenyx Pharmaceutical made up 0.02% of Pictet Asset Management's portfolio in Q2 2026, its #504 holding.
  • Pictet Asset Management first reported a position in Ultragenyx Pharmaceutical in Q3 2023 and has held it in 12 quarters since.
  • Pictet Asset Management's Ultragenyx Pharmaceutical position peaked at $61.9M in Q2 2025.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.